{"filing":{"accession_number":"0001193125-26-245163","cik":"0001802768","ticker":"RPRX","company_name":"Royalty Pharma plc","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"d131735d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1802768/000119312526245163/d131735d8k.htm"},"events":[{"id":8421,"run_id":7390,"accession_number":"0001193125-26-245163","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Royalty Pharma entered into a material definitive agreement for a $1.8 billion unsecured revolving credit facility that refinances and replaces an existing credit agreement, with a 5-year maturity and customary financial covenants, representing a significant capital structure change affecting the company's liquidity and financial flexibility.","company_name":"Royalty Pharma plc","ticker":"RPRX","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2304,"accession_number":"0001193125-26-245163","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure describes entry into a material definitive agreement—a $1.8 billion unsecured revolving credit facility that refinances and replaces an existing credit agreement. While the primary event is a refinancing (not a traditional M\u0026A transaction), the Item 1.01 classification and the materiality of the credit facility amount and terms make this a material financing event. The facility includes customary financial covenants and a 5-year maturity, indicating a significant capital structure change that would affect investor assessment of the company's liquidity and financial flexibility.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:21:14.865392+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2305,"accession_number":"0001193125-26-245163","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, indicating a material acquisition, disposition, merger, or change of control transaction. Item 1.01 is the standard disclosure vehicle for M\u0026A activity. Without access to the full Item 1.01 text, the cross-reference structure strongly suggests an M\u0026A event that creates direct financial obligations, making this material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:21:14.865392+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2304,"accession_number":"0001193125-26-245163","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure describes entry into a material definitive agreement—a $1.8 billion unsecured revolving credit facility that refinances and replaces an existing credit agreement. While the primary event is a refinancing (not a traditional M\u0026A transaction), the Item 1.01 classification and the materiality of the credit facility amount and terms make this a material financing event. The facility includes customary financial covenants and a 5-year maturity, indicating a significant capital structure change that would affect investor assessment of the company's liquidity and financial flexibility.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:21:14.865392+00:00","company_name":"Royalty Pharma plc","ticker":"RPRX","filing_date":"2026-05-28"},{"id":2305,"accession_number":"0001193125-26-245163","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, indicating a material acquisition, disposition, merger, or change of control transaction. Item 1.01 is the standard disclosure vehicle for M\u0026A activity. Without access to the full Item 1.01 text, the cross-reference structure strongly suggests an M\u0026A event that creates direct financial obligations, making this material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:21:14.865392+00:00","company_name":"Royalty Pharma plc","ticker":"RPRX","filing_date":"2026-05-28"}]}